Salute e Benessere
3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics
"This study represents a major leap forward in our understanding of ADHD therapeutics," commented Dr. Karl Karlsson , CEO of 3Z Pharmaceuticals, emphasizing the study's significance, "By leveraging advanced metabolomics and lipidomics, we have uncovered a shared metabolic signature across treatments—highlighting the potential of L-type calcium channel modulation as the foundation for a new non-stimulant ADHD therapy. These findings not only validate our drug discovery platform but also pave the way for much-needed new treatment options."
To bridge this gap, 3Z Pharmaceuticals employed an advanced systems biology approach, integrating cross-species analysis using the zebrafish adgrl3.1 ADHD model with targeted metabolomic profiling to explore common metabolic pathways underlying ADHD therapeutics.
Key Findings from the Study:
https://www.sciencedirect.com/science/article/pii/S0022356525396163
Building on these findings, 3Z Pharmaceuticals is advancing its metabolomics-driven approach to CNS drug discovery, focusing on refining therapeutic targets and optimizing treatment strategies for future clinical development.
3Z Pharmaceuticals, based in Reykjavik , Iceland, identifies and advances next-generation therapies for CNS disorders through both novel discovery and strategic repurposing. The company is pioneering a state-of-the-art drug development platform that integrates high-throughput screening, multi-omics, and AI analytics.
With a strong focus on translational validation, 3Z de-risks CNS drug development by combining multi-species assessment with human Mendelian randomization, polygenic risk scoring, and genetic studies to enhance clinical predictability.
For more information or media inquiries, please contact:
Karl Karlsson
CEO, 3Z Pharmaceuticals
Karlsson@3z.is
+354 825 66467
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/3z-ehf/r/3z-pharmaceuticals-publishes-breakthrough-study-on-shared-metabolic-pathways-in-adhd-therapeutics,c4110316
View original content:https://www.prnewswire.co.uk/news-releases/3z-pharmaceuticals-publishes-breakthrough-study-on-shared-metabolic-pathways-in-adhd-therapeutics-302383503.html